Nobody wants to invest with slimey dirt bags.
REVERSE SPLIT to be announced soon.
Hype, endless hype - not one P3 trial completed in 37 years. NONE!!!!!!
NOTHING developed for Ebola - NOTHING will be developed for Zika.
Look for a similar drop ----- sub $4 this time.
"The ExteNET trial randomized 2,840 patients in 41 countries with early-stage HER2-positive breast cancer who had undergone surgery and adjuvant treatment with trastuzumab. After completion of adjuvant treatment with trastuzumab, patients were randomized to receive extended adjuvant treatment with either neratinib or placebo for a period of one year. Patients were then followed for recurrent disease, ductal carcinoma in situ, or death for a period of two years after randomization in the trial. The primary endpoint of the trial was invasive disease free survival (DFS). The results of the trial demonstrated that treatment with neratinib resulted in a 33% reduction of risk of invasive disease recurrence or death versus placebo (hazard ratio = 0.67, p = 0.009)."